Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The Journal of Biological Chemistry|April 22, 2009
The isomerase active site of cyclophilin A is critical for hepatitis C virus replicationUdayan Chatterji, Michael Bobardt, Suganya Selvarajah, et al.
Antimicrobial Agents and Chemotherapy|November 11, 2015
C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus ChallengeRonald S Veazey, Udayan Chatterji, Michael Bobardt, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 14, 2019
A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease ModelsJoseph Kuo, Michael Bobardt, Udayan Chatterji, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2012
Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivirJose A Garcia-Rivera, Michael Bobardt, Udayan Chatterji, et al.
Plos Pathogens|August 7, 2023
Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of K18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2Gary Ewart, Michael Bobardt, Bo Hjorth Bentzen, et al.
Retrovirology|July 5, 2006
Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120James M Binley, Stacie Ngo-Abdalla, Penny Moore, et al.
Plos One|November 10, 2010
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5ALotte Coelmont, Xavier Hanoulle, Udayan Chatterji, et al.
Chemistry & Biology|January 27, 2015
Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infectionMagnus Joakim Hansson, Steven James Moss, Michael Bobardt, et al.
Communications Medicine|October 14, 2022
Early SARS-CoV-2 dynamics and immune responses in unvaccinated participants of an intensely sampled longitudinal surveillance studyManjula Gunawardana, Simon Webster, Sofia Rivera, et al.
Hepatology (Baltimore, Md.)|February 28, 2008
The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virusRobert Flisiak, Andrzej Horban, Philippe Gallay, et al.
Pageof 4